Immune disorders are an important feature of patients with out-of-hospital cardiac arrest (OHCA) after return of spontaneous circulation (ROSC). However, the precise immune alterations in patients with OHCA that occur immediately after ROSC are unclear. In this study, we investigated human leucocyte antigen-DR (HLA-DR) expression on circulatory monocytes and B and T lymphocytes. Sixtyeight consecutive patients with OHCA with ROSC >12 hours were enrolled. Clinical data and 28-day survival were recorded. Peripheral blood samples after ROSC days 1 and 3 were analysed to evaluate HLA-DR expression. Fifty healthy individuals were enrolled as controls. Compared with levels in healthy individuals, HLA-DR expression on monocytes and B lymphocytes, but not on T lymphocytes, decreased on days 1 and 3 after ROSC. No significant difference in HLA-DR expression was detected between survivors and non-survivors on day 1. For 41 patients with expression data for days 1 and 3, HLA-DR expression on monocytes and B lymphocytes in non-survivors was lower than that in survivors on day 3. In non-survivors, the mean fluorescence intensities of HLA-DR on B lymphocytes and percentages of HLA-DR+ T lymphocytes were lower on day 3 than on day 1. On days 1 and 3, there were significant correlations between HLA-DR expression on monocytes and B lymphocytes and clinical indicators, such as time to ROSC, adrenaline dose, acute physiology, chronic health evaluation II and the sequential organ failure assessment. The decreases in HLA-DR expression on circulatory monocytes and B and T lymphocytes after ROSC may be involved in the observed immunosuppression in patients with OHCA.
The high rates of infections in patients with OHCA may be due to immune system suppression. However, exact changes in circulatory immune cells in patients with OHCA are unclear. One intrinsic innate immune response linked to adaptive immune cells involves antigen presentation. Antigen-presenting cells (APCs) can process and present antigens to CD4 helper T cells to initiate adaptive immunity. This process is closely related to major histocompatibility complex II (MHC-II) molecules. The MHC-II molecule human leucocyte antigen-DR (HLA-DR) functions as a vehicle for antigenic peptide presentation to complementary specific T cell receptors. This step is crucial for the development of sustained and adaptive immune responses to clear pathogens. 11 HLA-DR has been studied extensively in patients with septic and non-septic systematic inflammatory reaction syndrome and is associated with prognosis in septic patients and in trauma patients with nosocomial infections. [12] [13] [14] [15] [16] HLA-DR is therefore thought to be a valuable biomarker for evaluating immune responses in patients in critical condition, 17 suggesting that it may also be a valuable marker in patients with OHCA. Human leucocyte antigen-DR molecules are expressed on the surfaces of professional APCs, such as monocytes, B lymphocytes and dendritic cells, or non-professional APCs, such as T lymphocytes. 16, 18 Only two studies with limited sample sizes have demonstrated changes in HLA-DR expression on monocytes in patients with OHCA, 10, 19 and HLA-DR expression levels on B and T lymphocytes have not been reported. In this study, we explored early alterations in the circulatory immune system in patients with OHCA after ROSC; in particular, we evaluated HLA-DR expression on monocytes and B and T lymphocytes in circulation.
| METHODS

| Study participants
This study was approved by the local medical ethics committees including Beijing Chao-Yang Hospital, Beijing Shijingshan Hospital, Beijing Luhe Hospital and Beijing Friendship Hospital. The need for informed consent was waived because this was an observational study and biomarker expression levels were measured using residual blood samples after the completion of the routine tests each morning. From July to September 2016 and from March until September 2017, patients with OHCA admitted to the emergency departments of these hospitals were evaluated for possible enrolment. OHCA was recognized according to the 2015 International Consensus on Cardiopulmonary Resuscitation. 20 In general, rescuers are to begin CPR if an adult is unresponsive and not breathing normally (disregarding occasional gasps). Our inclusion criteria were as follows: ROSC > 12 hours and Glasgow Coma Score <8 after ROSC. The exclusion criteria were <18 years of age, obvious infection of any organ or tissue, terminal stage of disease (malignant cancer of any type, acquired immunodeficiency syndrome) or the receipt of immunosuppressive therapy in the last 3 months. All patients were treated according to the 2015 International Consensus on Cardiopulmonary Resuscitation. 21 Additionally, approximately age-and sex-matched healthy individuals who underwent a physical health examination were enrolled as controls.
| Data collection
Subject data, including demographics, resuscitation data and clinical and laboratory parameters, were recorded. Resuscitation data included the prehospital adrenaline dose, initial cardiac rhythm and time to ROSC. Laboratory parameters included blood cell routine test results and blood biochemical test results on admission (within 4 hours after OHCA, day 0), the morning following admission (close to 24 hours, day 1) and day 3. Acute physiology and chronic health evaluation II (APACHE II) and sequential organ failure assessment (SOFA) scores were calculated to determine severity. Residual blood samples after the completion of routine clinical tests or physical health examinations were collected, kept at 4°C during transport and storage and used to analyse HLA-DR expression on monocytes and B and T lymphocytes. During follow-up, 28-day survival was recorded.
| Flow cytometry
Human leucocyte antigen-DR expression on monocytes and lymphocytes was analysed separately in two tubes with heparin lithium anticoagulant blood samples. Briefly, a 100-μL blood sample was stained for 20 minutes in the dark. Erythrocytes were lysed for 10 minutes using red blood cell lysis buffer, and the debris was washed away. The following monoclonal antibodies and their isotype controls were used: eFluor 450-labelled anti-HLA-DR (1 μL; eBioscience, San Jose, CA, USA), APC-H7 labelled anti-CD3 (1 μL; BD Bioscience, San Diego, CA, USA), PElabelled anti-CD19 (1 μL; eBioscience) and PE-labelled anti-CD14 (5 μL; BD Bioscience), per 100 μL of whole blood. Samples were measured using the Gallios ™ Flow
Cytometer (Beckman Coulter, Inc., Brea, CA, USA) and analysed using Gallios Software version 1.0. Monocytes were identified by CD14+ staining (Figure 1A ). Lymphocytes were gated by forward scatter and side scatter ( Figure 1B) . T lymphocyte subsets were further distinguished by CD3+ staining, and B lymphocyte subsets were distinguished by CD19+ staining. At least 3000 HLA-DR+ lymphocytes (including T and B lymphocytes) or monocytes were analysed for each sample. The threshold was defined using an isotype control. Results are expressed as percentages and mean fluorescence intensities (MFIs). The MFI of the isotype control from every sample was determined to ensure the comparability and reproducibility of results.
| Statistical analyses
All data were analysed using SPSS version 22.0 (SPSS Inc., Chicago, IL, USA). For normally distributed data, continuous variables are presented as means ± standard deviation. For parameters with a skewed distribution, results are expressed as medians (25th and 75th percentiles). The Kruskal-Wallis test was applied for multigroup comparisons, and the Mann-Whitney U test was used for betweengroup comparisons. The Wilcoxon signed rank test was used for paired sample comparisons. Qualitative parameters were analysed using a 2 × 2 contingency table, and χ 2 or
Fisher's exact tests were used for further analyses. Correlations were analysed by Spearman's rank correlation coefficients. All statistical tests were two-tailed, and P < 0.05 was considered statistically significant.
| RESULTS
| Patient characteristics
Sixty-eight patients with OHCA and 50 healthy individuals were included in the study. Demographic and clinical characteristics of patients with OHCA are presented in Table 1 . In this study, other causes of OHCA included poisoning, hypokalaemia and unexplained causes. According to 28-day survival, patients with OHCA were divided into survivors and non-survivors, and the characteristics of initial resuscitation are shown in Table 2 . Of the 68 patients with OHCA, HLA-DR expression in 13 patients who survived <3 days was analysed only on day 1. Of the 55 patients who survived longer than 3 days, HLA-DR expression levels were analysed in 11 patients on day 1 only, three patients on day 3 only and 41 patients on days 1 and 3. According to 28-day survival, the 41 patients with OHCA with results for days 1 and 3 were divided into survivors and non-survivors, and demographic and initial resuscitation data are shown in Table 3 . These 41 patients were analysed by paired sample comparisons to evaluate dynamic changes.
F I G U R E 1 Representative flow dot plots of HLA-DR expression on monocytes (A) and B and T lymphocytes (B). HLA-DR expression is
shown by the percentage and mean fluorescence intensities on the vertical axis QI ET AL.
| Changes in circulatory white blood cell subsets in the first 3 days after ROSC
After ROSC, sharp changes in white blood cell counts were detected. Compared with healthy individuals, total white blood cell, neutrophil and monocyte counts for patients with OHCA were significantly higher on days 1 and 3 after ROSC ( Figure 2A1 -C1). Lymphocyte counts, including the T/B lymphocyte ratio, decreased significantly on days 1 and 3 ( Figure 2D1 ,E1). No significant differences in white blood cell counts, including subsets, were observed between survivors and non-survivors on day 1 ( Figure 2A2-E2 ). In addition, a dynamic analysis showed that the T/B lymphocyte ratio and white blood counts, including neutrophil and monocyte subsets, in non-survivors exhibited a rapid decrease on day 3 ( Figure 2A3 -E3).
| HLA-DR expression on monocytes of patients with OHCA after ROSC
Compared with those of healthy individuals, patients with OHCA showed a lower percentage of HLA-DR-positive monocytes and a lower HLA-DR MFI on monocytes on day 1 after ROSC ( Figure 3A1 -2), and these parameters remained at low levels on day 3. On day 1, HLA-DR expression on monocytes showed no significant difference between the survivors and non-survivors ( Figure 3B1 -2). In 41 patients with OHCA included in the dynamic expression analyses, we did not detect a significant difference in HLA-DR expression between days 1 and 3 in the survivors (n = 17) or in the non-survivors (n = 24). Interestingly, in these 41 patients, both the percentage of HLA-DR-positive monocytes and the MFI of HLA-DR on monocytes were 
| HLA-DR expression on B lymphocytes in patients with OHCA after ROSC
Like in monocytes, the membrane surfaces of nearly all B lymphocytes of healthy individuals expressed HLA-DR with a high intensity. Compared with healthy individuals, patients with OHCA showed slightly lower percentages of HLA-DR-positive B lymphocytes on day 1 after ROSC, and the MFI of HLA-DR on B lymphocytes showed a significant decrease ( Figure 4A1-2) . The percentage of HLA-DR-positive B lymphocytes and the MFI of HLA-DR on B lymphocytes remained low, with no further decreases on day 3. On day 1, no significant difference in HLA-DR expression on B lymphocytes was found between the survivors and non-survivors ( Figure 4B1-2 ). An analysis of dynamic expression patterns in 41 patients with OHCA revealed that the MFI of HLA-DR on B lymphocytes in the non-survivors was lower on day 3 than on day 1. Additionally, in these 41 patients, the MFI of HLA-DR on B lymphocytes of the survivors was higher than that of the non-survivors on day 3 ( Figure 4C1-2 ).
| HLA-DR expression on T lymphocytes of patients with OHCA after ROSC
On days 1 and 3 after ROSC, the percentage of HLA-DRpositive T lymphocytes and the MFI of HLA-DR on T lymphocytes in patients with OHCA were not significantly different from those of healthy individuals ( Figure 5A1-2) . HLA-DR expression on T lymphocytes also showed no significant difference between the survivors and non-survivors ( Figure 5B1-2) . Furthermore, a dynamic observation of HLA-DR expression on lymphocytes in 41 patients with OHCA revealed that the percentage of HLA-DR-positive T lymphocytes, and not the MFI of HLA-DR, on day 3 was lower than that on day 1 among the non-survivors (Figure 5C1-2 ).
| Correlation between HLA-DR and clinical indicators on days 1 and 3 after ROSC
Obvious correlations were found between HLA-DR expression on monocytes and B lymphocytes and clinical indicators, such as time to ROSC, dose of adrenaline, APACHE II and SOFA, on days 1 and 3 after ROSC (see Table 4 for correlation coefficients). In addition, dynamic changes in these correlation coefficients were observed in survivors and non-survivors (Table 5) . Comparatively, no significant statistical or dynamic correlations were found between HLA-DR expression on T lymphocytes and clinical indicators.
| DISCUSSION
Patients with OHCA have impaired immunity, characterized by high infection rates and diverse infection sources. evaluating the rapidly evolving immune system status, 17, 22 emphasizing the need to evaluate changes in HLA-DR expression in circulation after ROSC. In our study, we found that HLA-DR expression levels on circulatory monocytes and B and T lymphocytes of patients with OHCA decrease in the early period after ROSC, and these decreases may contribute to immunosuppression in patients with OHCA. In our study, on day 1 after ROSC, HLA-DR expression on monocytes and B lymphocytes, but not on T lymphocytes, decreased significantly; however, no significant difference was found between survivors and non-survivors. On day 3, in the survivors, HLA-DR expression on monocytes and B lymphocytes remained low but showed no further decrease from the levels observed on day 1. In the non-survivors, on day 3, HLA-DR expression on B and T lymphocytes further decreased from the levels observed on day 1, and HLA-DR expression levels on monocytes and B lymphocytes were lower in non-survivors than in survivors.
Our finding that HLA-DR expression on monocytes decreased after ROSC is consistent with previous results. 10, 19 However, unlike in the previous reports, we did not find a significant difference in HLA-DR expression on monocytes between survivors and non-survivors on day 1. One explanation for this discrepancy is that the time to ROSC was similar for the survivors and non-survivors in this study, suggesting similar systematic ischaemia. We further observed dynamic changes in HLA-DR expression in 41 patients with OHCA who survived longer than 3 days, but we did not detect a significant difference between days 1 and 3 in the survivors or in the non-survivors. However, HLA-DR expression on monocytes in the survivors was higher than that in the non-survivors on day 3. Similar changes in HLA-DR expression between survivors and non-survivors have been reported in a previous study. 19 Therefore, it is theoretically conceivable that more critical systematic ischaemia due to OHCA leads to a more substantial decrease in HLA-DR expression on monocytes. Decreased HLA-DR expression is a potential biomarker of monocyte deactivation, as evidenced by the relationship between decreased HLA-DR expression and impairment of monocyte functions, including a loss of pro-inflammatory properties and decreased capacity to induce antigen-specific T cell responses. 23, 24 These data together indicate that despite elevated monocyte counts after ROSC, the function of monocytes is impaired due to decreased HLA-DR expression and thereby severe dysfunctions in antigen presentation and increased susceptibility to pathogens. Similar to monocytes, B lymphocytes also function as professional APCs. Characterizing changes in HLA-DR expression on B lymphocytes is important because B lymphocytes not only have an antigen presentation function but also produce the antibodies required to eradicate infective microorganisms. In the present study, the percentage of HLA-DR-positive B lymphocytes showed only a slight decrease after ROSC. We observed a more obvious decrease in the MFI of HLA-DR on the membrane surface of B lymphocytes. After ROSC, the MFI of HLA-DR on B F I G U R E 2 Changes in circulatory white blood cell subsets in the first three days after ROSC. A1-E1: the changes in white blood cell counts in total 68 patients with OHCA on days 1 and 3 after ROSC; A2-E2: the comparison of white blood cell counts between survivors and non-survivors on day 1. A3-E3: dynamic changes in white blood cell counts in survivors and non-survivors. #P < 0.01 compared with healthy control group ★ P < 0.05 compared with OHCA group (day = 1) lymphocytes decreased significantly until day 3. On day 1, no significant difference was found between the survivors and non-survivors. However, HLA-DR expression on B lymphocytes in the non-survivors decreased further on day 3. MHC-II molecules can be upregulated in B lymphocytes by stimulation via a number of pathogen-associated molecular pattern-sensitive pathways as well as via the B lymphocyte receptor-mediated activation pathway. [25] [26] [27] Thus, the upregulation of MHC-II molecules reflects B lymphocyte activation to an antigen-presenting function, and the downregulation is associated with impaired function. In severely injured patients, HLA-DR expression on B lymphocytes decreases, and persistent low expression is associated with the occurrence of sepsis in trauma patients. 28 Therefore, the downregulation of HLA-DR on B lymphocytes might also be involved in the immunodeficiency observed after OHCA. In our study, we also analysed HLA-DR expression on T lymphocytes. Activated T lymphocytes can express MHC-II molecules. 29, 30 Therefore, T lymphocytes have potential antigen presentation functions, which is evident from the fact that activated T cells are capable of antigen uptake and subsequent presentation of the processed antigens to other T cells. [31] [32] [33] Interactions between T lymphocytes may play an important regulatory role in immune responses. We found that compared with healthy individuals, the patients with OHCA did not show any obvious changes in HLA-DR expression on T lymphocytes after ROSC. On day 1, there was also no significant difference in HLA-DR expression on T lymphocytes between survivors and non-survivors. However, on day 3, the percentage of HLA-DR-positive T lymphocytes in the nonsurvivors was lower than that on day 1. These results can be interpreted in two ways: (a) The potential antigen presentation function of T lymphocytes is impaired or (b) T lymphocyte activation is suppressed after ROSC. Indeed, the downregulated reaction and proliferation ability of T lymphocytes from resuscitated patients to mitogenic stimulation imply the suppression of T lymphocyte activation. 3, 34 We found obvious correlations between clinical indicators and HLA-DR expression on monocytes and B lymphocytes, not on T lymphocytes. These clinical indicators, such as time to ROSC, dose of adrenaline, APACHE II and SOFA, were associated with systemic ischaemiahypoxia to some extent. Therefore, more critical patients with more severe systemic ischaemia-hypoxia exhibited more substantial decreases in HLA-DR expression, as predicted. However, further studies are needed to verify these correlations between HLA-DR expression on T lymphocytes and clinical indicators using larger diversified samples. Nevertheless, our findings clearly establish that HLA-DR expression on circulatory immune cells decreases after ROSC, especially on professional APCs.
The precise mechanism underlying HLA-DR changes in patients with OHCA is unknown. In sepsis, multiple mechanisms are involved in the downregulation of HLA-DR, including anti-inflammatory mediators, such as IL-10, 35 stress hormones, such as cortisol, 36 and a failure of cell metabolism. 37 Increased IL-10 and cortisol levels are common in patients with OHCA after ROSC, especially in non-survivors. [3] [4] [5] 38, 39 However, little is known about immune cell metabolism in patients with OHCA. These patients share similarities with septic patients, for example microcirculation dysfunction or tissue hypoxia. Therefore, factors that lead to a decrease in HLA-DR expression in sepsis may also influence HLA-DR expression in patients with OHCA. It is possible that persistently elevated IL-10 and cortisol levels, more severe systematic hypoxia or other factors in non-survivors lead to further downregulation on day 3. Further studies are needed to evaluate these factors. This study had some limitations. First, owing to the complex clinical features, such as fever of central origin/ therapeutic hypothermia, the impact of stress on white blood cells and interobserver agreement in the interpretation of chest radiographs, confirmation of an infection is difficult. 40, 41 Therefore, we did not analyse the correlation between T lymphocyte subsets and infection, and only emphasize early changes in HLA-DR expression. Second, the sample size was fairly small, and the heterogeneity among patients was large. Various factors, such as no-flow time, could influence the results. A larger number of samples are necessary to confirm the results of this study and to definitively determine the impact of particular factors. Third, we observed early changes but did not perform dynamic observations thereafter. Dynamic observations spanning a longer duration would be helpful to understand the significance of HLA-DR expression in evolving immunity after ROSC. Forth, we did not perform the calibration of flow cytometer every time, which may influence the comparability and reproducibility of results.
| CONCLUSIONS
The expression of HLA-DR on monocytes and T and B lymphocytes decreases in the circulation of patients with OHCA. On day 1 after ROSC, a rapid decrease in HLA-DR expression occurs on monocytes and B lymphocytes. On day 3, the expression of HLA-DR on monocytes as well as on T and B lymphocytes further decreases in nonsurvivors. Our findings suggest that downregulated HLA-DR expression in the circulation may be involved in the immunosuppression observed in patients with OHCA after ROSC. 
ACKNOWLEDGMENT
